UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 218

Sortiert nach

A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production

Investigational new drugs, 2013-06, Vol.31 (3), p.493-505

2013

Link zum Volltext

Verfügbarkeit prüfen

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

Investigational new drugs, 2013-10, Vol.31 (5), p.1158-1168

2013

Link zum Volltext

Verfügbarkeit prüfen

The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice

Investigational new drugs, 2013-02, Vol.31 (1), p.192-199

2013

Link zum Volltext

Verfügbarkeit prüfen

Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer

Investigational new drugs, 2013-02, Vol.31 (1), p.46-58

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization and preclinical development of LY2603618: a selective and potent Chkl inhibitor

Investigational new drugs, 2014, Vol.32 (2), p.213-226

2014

Link zum Volltext

Verfügbarkeit prüfen

AD-053.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L

Investigational new drugs, 2014, Vol.32 (6), p.1155-1166

2014

Link zum Volltext

Verfügbarkeit prüfen

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities

Investigational new drugs, 2014-12, Vol.32 (6), p.1071-1082

2014

Link zum Volltext

Verfügbarkeit prüfen

The inhibitor of Ca2+-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB

Investigational new drugs, 2013-04, Vol.31 (2), p.452-457

2013

Link zum Volltext

Verfügbarkeit prüfen

Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach

Investigational new drugs, 2013-08, Vol.31 (4), p.881-890

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

Investigational new drugs, 2013-02, Vol.31 (1), p.136-144

2013

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of two 125I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma

Investigational new drugs, 2014-08, Vol.32 (4), p.587-597

2014

Link zum Volltext

Verfügbarkeit prüfen

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-KB and p70s6k, in patients with advanced solid tumors

Investigational new drugs, 2014, Vol.32 (6), p.1204-1212

2014

Link zum Volltext

Verfügbarkeit prüfen

Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats

Investigational new drugs, 2013-12, Vol.31 (6), p.1476-1486

2013

Link zum Volltext

Verfügbarkeit prüfen

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor 3 (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

Investigational new drugs, 2014, Vol.32 (3), p.555-560

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of the gamma secretase inhibitor R04929097 in patients with previously treated metastatic pancreatic adenocarcinoma

Investigational new drugs, 2014, Vol.32 (4), p.739-745

2014

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 1713-hydroxy steroid dehydrogenase type 5 17(3HSD5; AKR1C3)

Investigational new drugs, 2014, Vol.32 (5), p.860-870

2014

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model

Investigational new drugs, 2013-08, Vol.31 (4), p.801-811

2013

Link zum Volltext

Verfügbarkeit prüfen

Functional and molecular characterization of kinin B1 and B2 receptors in human bladder cancer: implication of the PI3Kγ pathway

Investigational new drugs, 2013-08, Vol.31 (4), p.812-822

2013

Link zum Volltext

Verfügbarkeit prüfen

Development of multidrug-resistance convertors : sense or nonsense?

Investigational new drugs, 2000-08, Vol.18 (3), p.205-220

2000

Link zum Volltext

Verfügbarkeit prüfen

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents

Investigational new drugs, 1997-01, Vol.15 (1), p.39-48

1997

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human breast cancer and ovarian cancer xenografts

Investigational new drugs, 2002-08, Vol.20 (3), p.241-251

2002

Link zum Volltext

Verfügbarkeit prüfen

Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane

Investigational new drugs, 1995-12, Vol.13 (4), p.327-332

1995

Link zum Volltext

Verfügbarkeit prüfen

Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration

Investigational new drugs, 2003-02, Vol.21 (1), p.55-62

2003

Link zum Volltext

Verfügbarkeit prüfen

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

Investigational new drugs, 1998-01, Vol.16 (2), p.121-128

1998

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel serum protein binding with high affinity to alpha-acid glycoprotein

Investigational new drugs, 1996, Vol.14 (2), p.147-151

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 218

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Immunology And Immunotherapy

ThemaHumans

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieInvestigational New Drugs

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(218)
Mit Volltextzugriff
(218)

Publikationsform

Artikel
(218)

Sprache

Englisch
(218)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Journals@Ovid Complete
(218)
Springer Nature - Complete Springer Journals
(218)
MEDLINE
(59)
IngentaConnect Journals
(38)

Menü

Weitere Dienste

Einstellungen

A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice

Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer

Characterization and preclinical development of LY2603618: a selective and potent Chkl inhibitor

AD-053.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities

The inhibitor of Ca2+-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB

Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

Evaluation of two 125I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-KB and p70s6k, in patients with advanced solid tumors

Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor 3 (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

A phase II study of the gamma secretase inhibitor R04929097 in patients with previously treated metastatic pancreatic adenocarcinoma

In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 1713-hydroxy steroid dehydrogenase type 5 17(3HSD5; AKR1C3)

Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model

Functional and molecular characterization of kinin B1 and B2 receptors in human bladder cancer: implication of the PI3Kγ pathway

Development of multidrug-resistance convertors : sense or nonsense?

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents

Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human breast cancer and ovarian cancer xenografts

Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane

Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

Docetaxel serum protein binding with high affinity to alpha-acid glycoprotein

Aktive Filter

Suchergebnisse filtern